| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 10.072 | 13.821 | 13.574 | 12.539 | 1.984 | 6.781 | 13.421 | 12.265 | 12.346 |
| Total Income - EUR | - | 10.072 | 13.821 | 13.574 | 12.539 | 1.984 | 6.781 | 16.317 | 12.362 | 12.425 |
| Total Expenses - EUR | - | 4.539 | 4.475 | 12.855 | 12.932 | 11.126 | 11.018 | 5.914 | 5.448 | 8.405 |
| Gross Profit/Loss - EUR | - | 5.534 | 9.346 | 719 | -393 | -9.142 | -4.237 | 10.403 | 6.915 | 4.021 |
| Net Profit/Loss - EUR | - | 5.231 | 8.932 | 312 | -769 | -9.196 | -4.440 | 9.914 | 5.542 | 2.940 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Cavasimedica Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 132 | 915 | 27.787 | 18.592 | 10.116 | 1.978 | 0 | 0 | 0 |
| Current Assets | - | 10.021 | 18.787 | 9.900 | 18.353 | 17.495 | 7.685 | 16.014 | 18.302 | 21.183 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 1.347 | 6.516 | 3.292 | 1.924 | 1.628 | 2.899 | 628 | 3.428 | 2.680 |
| Cash | - | 8.674 | 12.271 | 6.608 | 16.429 | 15.867 | 4.786 | 15.386 | 14.874 | 18.503 |
| Shareholders Funds | - | 5.275 | 14.117 | 14.170 | 13.127 | 3.682 | -840 | 9.071 | 14.585 | 17.393 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 4.878 | 5.585 | 23.518 | 23.819 | 23.930 | 10.504 | 6.943 | 3.716 | 3.789 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Cavasimedica Srl